SAN FRANCISCO, June 13, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (“23andMe” or the “Company”) (OTC: MEHCQ), a leading human genetics and biotechnology company, today announced that it has entered ...

AI data centers need energy, and that’s what’s made the stock price of aptly-named NRG $NRG rise 88% in the past year ...

"Lymphopenia has long been recognized as a major driver and predictor of early mortality in cancer—yet until now, it has ...

Regeneron Pharmaceuticals logged a 4.0% change during today's afternoon session, and is now trading at a price of $513.17 per ...

Regeneron stock just slipped on a banana peel, hitting a 52-week low at $493.15 before closing at $496.06. Despite this dip, ...

Apple Inc.'s stock has struggled to find positive momentum this year, and analysts at Needham & Company don't see major catalysts ahead that can help put shares on a better course.

Adam Turnquist, a technical strategist at LPL Financial, said the recovery in stock-market breadth is a particularly convincing bullish "tell" suggesting that the market's recovery appears to be on ...

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

23andMe has said it wants to allow new bids by both parties with a deadline of 12th June, according to a Financial Times ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) announced favorable Phase 3 trial results for itepekimab and entered a significant licensing agreement with Telesis Bio, enhancing its R&D capabilities.

According to InvestingPro analysis, the stock appears undervalued based on its Fair Value calculation, trading at an attractive P/E ratio of 14.36. For deeper insights into Regeneron’s valuation and ...

The firm had not factored itepekimab revenues into their valuation model, and as such, the mixed study outcomes do not alter their assessment of the company’s financial trajectory. Currently trading ...